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Background: JMML is a rare, highly aggressive clonal
myeloproliferative disorder typically diagnosed in infants
and young children. Allogeneic HSCT is widely accepted as
the standard curative therapy for JMML, but success is
limited by engraftment failure or disease relapse. Five-year
overall survival ranges from 50-55%.
Objective: Evaluate our single center allogeneic HSCT out-
comes for JMML.
Methods: We retrospectively reviewed data on all JMML
patients who received allogeneic HSCT at our center from
1998-2013. Data collected were age at diagnosis and HSCT,
time to HSCT, sex, race/ethnicity, conditioning regimen, stem
cell source, total nucleated cell dose, graft-versus-host dis-
ease (GVHD) prophylaxis, time to neutrophil (absolute
neutrophil count, ANC) and platelet (PLT) engraftment,
presence of acute and/or chronic GVHD, relapse, cause of
death, and last time of follow-up. Descriptive statistics were
used for data analysis.
Results: Eleven patients were diagnosed with JMML and
received allogeneic HSCT over the last 15 years in our center.
Median age at diagnosis was 18.6 (range 2.9-42.1) months.
Six of 11 (54.5%) were males. Eight of 11 (72.7%) were His-
panic, 2/11 White (18.2%), and 1/11 Black (9.1%). Median age
at HSCT was 26.2 months (range 4.1-51.0) with median time
to HSCT 6.1 months (range 1.2-17.1). All received myeloa-
blative conditioning; 8/11 (72.7%) received busulfan, cyclo-
phosphamide, and melphalan with 5/11 (45.5%) receiving
ATG. GVHD prophylaxis was CsA+steroids (4), CsA+MMF (1),
and CsA+MTX (1) and tacrolimus+MTX (5). Stem cell source
was unrelated umbilical cord blood (UCB) (7) and bone
marrow (BM) (4). UCB HLA-disparities were 5/6 (5), 4/6 (1),
and 3/6 (1). Three of 4 received matched related donor
(MRD) BMwhile 1 received matched unrelated donor (MUD)
BMT. Median time to ANC > 500/mL was 21 days, to PLT
>20,000/mL was 33 days, and to PLT >50,000/mL was 44.5
days. One patient (UCB) had engraftment failure and
received a 2nd HSCT with UCB after 200 cGy total body
irradiation+ﬂudarabine+ATG. Acute GVHD occurred in 6/11
(54.5%), limited chronic GVHD in 2/11 (18.2%) and extensive
chronic GVHD in 1/11 (9.1%). With a median follow-up of 4.2
(range_0.1-15.2) years, 8/11 patients are alive (72.7%). Cause
of death was progression to AML (1), sinusoidal obstructive
liver syndrome and HHV6 encephalitis (1) and chronic GVHD
with bronchiolitis obliterans (1).
Conclusions: The overall survival for JMML in our center
(72.7%) over the last 15 years is comparable to published
data. Despite historically poor disease-free survival, nopatients have experienced recurrent JMML post-HSCT in our
cohort. We hypothesize that this observed trend toward
superior survival may be due to undeﬁned favorable char-
acteristics in our predominantly Hispanic patient population
and younger age at diagnosis. Our experience supports the
use of HLA-mismatched UCB for unrelated donor HSCT in
JMML.
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Introduction: Failure to harvest sufﬁcient stem cells from
either Bone marrow (BM) or peripheral blood is a rare but
known impasse in stem cell transplantation (SCT). If second
boost is not given within 96 hours then chances of rejection
post second SCT are very high. Plerixafor (Mozobil) is an
effective drug for rapid (within 24 hr) stem cell mobilizer as
it reduces CD34+ hematopoietic stem cells anchoring to the
BM microenvironment through reversible inhibition of the
SDF-1a/CXCR4 axis.
Case: A 4-year-old girl of thalassemia major underwent allo-
SCT from a 6/6 loci HLA-identical 17 year old sister. Pre-
transplant work-up showed no discernible pathology except
bidirectional major ABO mismatch. Conditioning regimen
consisted of intravenous busulphan (12.8 mg/kg),cyclo-
phosphamide (200mg/kg) and ATG (90mg/kg). Pre depletion
and after red cell and plasma depletion, harvested CD34+ cell
dose was 2 and 0.5 million/kg/recipient respectively. In view
of the failed BM harvest, a decision was eventually made,
after obtaining the consent of the parents, to attempt donor
CD34+ cell mobilization with plerixafor and G-CSF. The
donor received G-CSF (5 mcg/kg s.c.) for 3 consecutive days
at 1800 hr, while plerixafor (240 mcg/kg s.c.) was given 15 hr
later, after last dose of G-CSF. Five hour after plerixafor
dosing, the donor’s WBC had reached 64.0 x 109/L. The har-
vested CD34+ cell dose of 17.6 x 106/kg/recipient infused.
Donor tolerated plerixafor well without any adverse effects.
Her neutrophil and platelets engrafted on day +19 and +21
respectively. The patient and donor remain well 2 months
after SCT. Donor would be followed every 6 monthly for next
3 years for any long term adverse effects of plerixafor.
Conclusion: Our case highlights that plerixafor is an effec-
tive agent for rapid PBSC mobilization from a normal healthy
donor, if initial BM harvest fails. However, donor should be
monitored for the long term safety of plerixafor.
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Background: Although management of CML has changed
dramatically in the era of tyrosine kinase inhibitors (TKIs),
